What is Leerink Partnrs’ Forecast for ORKA FY2028 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Investment analysts at Leerink Partnrs issued their FY2028 earnings estimates for shares of Oruka Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings of ($2.92) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($1.69) per share.

A number of other analysts have also recently commented on ORKA. Stifel Nicolaus initiated coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. Wedbush assumed coverage on Oruka Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price target on the stock. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective on the stock. Leerink Partners initiated coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price target on the stock. Finally, TD Cowen started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set a “buy” rating on the stock. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA opened at $24.04 on Friday. The stock has a market cap of $29.09 million, a P/E ratio of -3.84 and a beta of 0.87. The firm’s 50-day simple moving average is $26.76. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ORKA. Geode Capital Management LLC purchased a new stake in Oruka Therapeutics during the 3rd quarter valued at about $343,000. The Manufacturers Life Insurance Company purchased a new stake in Oruka Therapeutics in the third quarter valued at approximately $1,037,000. Wellington Management Group LLP acquired a new stake in shares of Oruka Therapeutics in the third quarter worth $2,013,000. Janus Henderson Group PLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $5,840,000. Finally, Redmile Group LLC purchased a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $10,091,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.